Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

PURPOSE: Single-cycle melphalan 200 mg/m(2) and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a pros...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Stadtmauer, Edward A., Pasquini, Marcelo C., Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M., Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H., Shah, Nina, Vesole, David H., Vij, Ravi, Vogl, Dan T., Giralt, Sergio, Somlo, George, Krishnan, Amrita
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553842/
https://ncbi.nlm.nih.gov/pubmed/30653422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00685
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars